Cross-Border Drug Development: One Testing Lab for Both FDA and Health Canada Submissions
Introduction: Sponsors developing a drug for the North American market almost always end up filing in both the United States […]
Peptide API Scale-Up: From Milligram Discovery Batches to Kilogram GMP Production
Introduction Peptide API Scale-Up requires translating laboratory solid-phase synthesis into scalable, robust, and compliant current Good Manufacturing Practice (cGMP) processes
Peptide API Scale-Up: From Milligram Discovery Batches to Kilogram GMP Production Read More »
Peptide Drug Formulation Challenges: Lyophilization, Prefilled Syringes, and Injectable Stability
Peptide Formulation & Stability Peptide Drug Formulation Challenges: Lyophilization, Prefilled Syringes, and Injectable Stability By Anusha Sinha • July 20,
GLP-1 Peptide Manufacturing: Why Semaglutide and Tirzepatide Are Straining Global CDMO Capacity
Introduction Global contract development and manufacturing organization (CDMO) capacity is under severe pressure because the unprecedented multi-ton demand for semaglutide
Solid-Phase vs Liquid-Phase vs Hybrid Peptide Synthesis: Choosing the Right Technology for GMP Manufacturing
Introduction Developing therapeutic peptides within a regulated environment requires selecting a synthetic strategy that effectively balances chemical scalability with stringent
CDMO Services for Generic Oral Solid Dosage Forms: Tablets, Capsules, and Modified-Release ANDA Programs
Introduction Sponsors of generic drugs can improve their time-to-market and increase the likelihood of regulatory approval by utilizing comprehensive CDMO
CDMO Services for Generic Ophthalmic Drug Products: Sterile Fills, Container Closure, and ANDA Strategy
Introduction This comprehensive research report examines the advanced scientific, aseptic manufacturing, and regulatory strategies necessary for the successful development and
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ?
Introduction The distinction between a Generic Drug vs Biosimilar forms the core scientific and regulatory boundary separating chemically synthesized small-molecule
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ? Read More »
CMC Strategy for Complex Generic Injectables: What a CDMO Should Deliver
Introduction: A robust CMC Strategy for Complex Generic Injectables is one of the most important factors influencing successful ANDA approval.
CMC Strategy for Complex Generic Injectables: What a CDMO Should Deliver Read More »
Generic Drug Development for Poorly Soluble APIs: CDMO Approaches Using ASD, Nano, and Lipid Systems
Introduction Generic Drug Development for Poorly Soluble APIs requires advanced Contract Development and Manufacturing Organization (CDMO) strategies to address the